PwC’s Pharmaceutical & Life Sciences network is pleased to present you with our ninth issue of the Asia-Pacific Pharmaceutical & Life Sciences industry newsletter.
The newsletter aims to keep you informed of the latest developments in the industry for pharmaceutical, biotechnology, medical device, diagnostics and healthcare companies. Our second newsletter for the 2012 calendar year once more highlights a number of developments of direct interest to Pharmaceutical & Life Sciences companies that have impacted the industry in the recent months.
In our Compliance section we report on Australia’s proposed update to the industry code of conduct for marketing of pharmaceuticals within the industry.
Our section on Pricing & reimbursement developments includes some further articles on Government price cuts within major markets in the region, as well as some anti-counterfeit initiatives going on in India.
Finally, in our Tax section, we outline the finalised retrospective changes to Transfer Pricing rules in Australia, look at further guidance on ‘beneficial owner’ status in China, India’s new General Anti Avoidance Rules, changes in Taiwan’s taxation of shares and securities and some safe harbour provisions in Singapore.